Regulatory & Industry
| 3 min read
This year’s New Product Award winners reflect growing demand for tools that improve throughput, reproducibility, and hands-free operation in the lab.
| 3 min read
A policy update removes a longstanding barrier for medical device sponsors and signals a broader shift that could eventually reshape how drug and biologic developers approach evidence generation.
| 5 min read
Disruptions to key Middle East logistics corridors are rippling through pharmaceutical supply chains, raising costs and testing resilience, but not yet triggering shortages.
| 5 min read
Industry leaders at the Advanced Therapies conference outline how early collaboration, funding, and culture shape whether breakthroughs reach patients.
| 5 min read
Ireland’s model for advanced therapy manufacturing integrates academic research, workforce development, and regulatory bodies to streamline the production of complex biologics.
| 5 min read
Automation, digital manufacturing, and regulatory reform are reshaping how the UK competes in cell and gene therapy as the field moves toward routine delivery.
| 3 min read
Tariff-free US access and pricing reforms give the UK a potential edge in an uncertain global market.
| 5 min read
While faster reviews could bring life-saving treatments to patients sooner, compressed timelines could also limit regulatory scrutiny and strain FDA resources.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 5 min read
The life sciences sector contributes billions to the economy, but current policy and international factors are threatening growth.
| 3 min read
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
